Technical Analysis for LGVN - Longeveron Inc.

Grade Last Price % Change Price Change
C 8.0 8.70% 0.64
LGVN closed up 8.7 percent on Friday, February 26, 2021, on 1.97 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical LGVN trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Inside Day Range Contraction 8.70%
New 52 Week Closing High Bullish 4.58%
Hot IPO Pullback Bullish Swing Setup 24.42%
Hot IPO Pullback Bullish Swing Setup 17.65%
Inside Day Range Contraction 17.65%
New 52 Week Closing Low Bearish 29.87%
Hot IPO Pullback Bullish Swing Setup 29.87%
New 52 Week Low Weakness 29.87%
Down 3 Days in a Row Weakness 29.87%
Older End-of-Day Signals for LGVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Longeveron Inc. Description

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.


Classification

Sector: Other
Industry: Other
Keywords: Biotechnology Life Sciences Biology Stem Cells Cell Biology Cell Therapy Mesenchymal Stem Cell Acute Respiratory Distress Syndrome

Is LGVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.0
52 Week Low 6.01
Average Volume 367,143
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 7.11
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.73
Resistance 3 (R3) 9.58 8.87 9.44
Resistance 2 (R2) 8.87 8.43 8.94 9.34
Resistance 1 (R1) 8.43 8.16 8.65 8.58 9.25
Pivot Point 7.72 7.72 7.83 7.79 7.72
Support 1 (S1) 7.28 7.28 7.50 7.43 6.75
Support 2 (S2) 6.57 7.01 6.64 6.66
Support 3 (S3) 6.13 6.57 6.56
Support 4 (S4) 6.28